MedTrace Logo

Randomized Trial of Adult Participants With Generalized Anxiety Disorder

NCT03829241 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 881

Last updated 2024-05-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

Troriluzole

100 mg capsule

DRUG

Placebo

Placebo matched to troriluzole

Sponsors & Collaborators

  • Biohaven Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-19
Primary Completion
2020-01-14
Completion
2020-05-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03829241 on ClinicalTrials.gov